Business Wire

Toshiba Develops Next-Generation Lithium-ion Battery with New Anode Material

Jaa

Toshiba Corporation (TOKYO:6502), an industry leader in lithium-ion battery technology, today announced the development of its next-generation SCiB™, which uses a new material to double the capacity of the battery anode. The new battery offers high- energy density and the ultra-rapid recharging required for automotive applications, and will give a compact electric vehicle (EV) with a drive range of 320km*1 after only six minutes of ultra-rapid recharging—three times the distance possible with current lithium-ion batteries.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171002006637/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

Toshiba launched the SCiB™ as a safe, long-life, fast charging lithium-ion battery in 2008. Since then, the company has constantly refined the technology and improved real-world performance. For its next-generation SCiB™, Toshiba has developed a titanium niobium oxide anode material that has double the lithium storage capacity by volume of the graphite-based anodes generally used in lithium-ion batteries.

The new battery also offers high energy density and ultra-rapid recharging characteristics, and its titanium niobium oxide anode is much less likely to experience lithium metal deposition during ultra-rapid recharging or recharging in cold conditions—a cause of battery degradation and internal short circuiting.

Toshiba’s current SCiB™ employs a lithium titanium oxide anode, and is known for excellent operating characteristics in respect of safety, long life and rapid charging. It has found wide use in vehicles and industrial and infrastructure applications, including automobiles, buses, railroad cars, elevators and power plants. The high energy density of the battery, and its rapid recharging, have made important contributions to enhancing the convenience and promoting the spread of EV.

Building on this heritage, Toshiba has developed a proprietary method for synthesizing and disarranging crystals of titanium niobium oxide and storing lithium ions more efficiently in the crystal structure. The anode of the next-generation SCiB™ realized through this approach has double times the capacity of the anode of current lithium-ion batteries.

“We are very excited by the potential of the new titanium niobium oxide anode and the next-generation SCiB™,” said Dr. Osamu Hori, Director of Corporate Research & Development Center at Toshiba Corporation. “Rather than an incremental improvement, this is a game changing advance that will make a significant difference to the range and performance of EV. We will continue to improve the battery’s performance and aim to put the next-generation SCiB™ into practical application in fiscal year 2019.”

Rigorous testing of a 50Ah prototype of the new battery has confirmed that it retains the long life cycle, low-temperature operation, excellent safety and rapid recharging characteristics of the current SCiB™. The energy density by volume of battery is twice that of the current SCiB™. The next-generation SCiB™ maintains over 90% of its initial capacity after being put through 5,000 charge/discharge cycles, and ultra-rapid recharging can be done in cold conditions, with temperatures as low as minus 10oC, in only ten minutes.

Toshiba will continue to develop higher energy density batteries that extend the range of EVs and support ultra-rapid recharging, and aims to commercialize the next-generation SCiB™ in fiscal year 2019.

Part of the research work on the next-generation SCiBTM was subsidized by Japan’s New Energy and Industrial Technology Development Organization (NEDO).

*1 A compact EV with a 32kWh next generation SCiB™ in JC08 test cycle

About Toshiba

For over 140 years, Toshiba Corporation has contributed to a sustainable future by applying innovative technologies to value creation. Today, our business domains are centered on the essential infrastructure that supports modern life and society. Guided by the principles of The Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future”, Toshiba promotes global operations that contribute to realization of a world where generations to come can live better lives.
To find out more about Toshiba, visit www.toshiba.co.jp/worldwide/about/index.html

Contact information

Toshiba Corporation
Seiji Ishibashi, +81-3-3457-2100
PR & IR Division
media.relations@toshiba.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar16.12.2017 01:13Tiedote

Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 15:34Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712

Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 15:21Tiedote

Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr

Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 14:38Tiedote

A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L

Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 14:00Tiedote

Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a

AML BitCoin Enters Phase II of ICO15.12.2017 12:00Tiedote

NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme